Computed from published fixed rules, not a model's judgement — though one input, the count of high-severity risks, comes from the AI analysis below.
Not investment advice and not a price target: it scores the quarter's fundamentals, not the stock. Full methodology →
AI Takeaway
Corteva (CTVA) delivered solid FY2025 results with revenue rising 2.9% to $17.4B, net income surging 20.6% to $1.09B, and operating cash flow jumping 58.8% to $3.4B, reflecting improved cost discipline and stronger profitability.
Revenue
$17.4B
+2.92% YoY
EPS (Diluted)
$1.60
+23.08% YoY
Source: SEC XBRL
Corteva (CTVA) reported FY2025 revenue of $17.4B, up 2.9% year over year. Operating cash flow was $3.41B, up 58.8% year over year.
Last 4 quarters: 3 beats
| Quarter | Actual EPS (USD) | Consensus (USD) | Result |
|---|---|---|---|
| Jun 2026 | 2.30 | 2.27 | Beat +1.4% |
| Mar 2026 | 1.50 | 1.20 | Beat +25.4% |
| Dec 2025This filing | 0.22 | 0.22 | Miss -2.1% |
| Sep 2025 | -0.23 | -0.54 | Beat +57.6% |
Reported EPS of $0.22 versus the $0.22 analyst consensus — a -2.1% miss for Dec 2025.
Compiled by AI from this SEC filing
Total revenue grew 2.9% year-over-year to $17.4B in FY2025, reflecting continued demand for Corteva's seed and crop protection products across global agricultural markets. The growth was achieved despite a challenging macroeconomic backdrop for the agriculture sector.
Source: 10-K Income Statement
Cost of revenue declined 3.7% YoY from $9.53B to $9.17B, indicating meaningful improvement in manufacturing efficiency, input cost management, or favorable product mix. This reduction was a key driver of margin expansion in FY2025.
Source: 10-K Income Statement
Operating cash flow improved dramatically from $2.15B to $3.41B, a $1.26B increase, signaling strong earnings quality and improved working capital management. Cash and equivalents also rose 45.6% to $4.52B, strengthening the balance sheet.
Source: 10-K Cash Flow Statement
R&D expenses rose 5.1% to $1.47B, underscoring Corteva's commitment to innovation in seeds and crop protection. SG&A expenses increased 9.3% to $3.49B, which may reflect higher commercial investments or inflationary cost pressures on the selling and administrative side.
Source: 10-K Income Statement
Corteva returned $1.55B to shareholders in FY2025 through $1.07B in share buybacks (+6.1% YoY) and $475M in dividends (+3.7% YoY), demonstrating continued commitment to shareholder returns while maintaining a healthy balance sheet.
Source: 10-K Cash Flow Statement
Compiled by AI from this SEC filing · 1 high, 3 medium, 1 low
SG&A expenses grew 9.3% YoY to $3.49B, significantly outpacing revenue growth of 2.9%. If this trend continues, it could erode operating margins and offset gains from cost of revenue improvements. Management will need to demonstrate disciplined cost control in commercial and administrative functions.
Source: 10-K Income Statement
Total assets grew 4.9% to $42.85B while stockholders' equity grew only 1.5% to $24.14B, suggesting that asset growth is being partially funded by liabilities. Current liabilities rose 16.7% to $12.13B, outpacing current asset growth of 14.8%, which could tighten near-term liquidity if not managed carefully.
Source: 10-K Balance Sheet
ROE stands at approximately 4.5% and ROA at approximately 2.6%, which are relatively modest for a large-cap agricultural company. These low returns may reflect the capital-intensive nature of the business and ongoing integration or restructuring costs, but could also signal underutilization of assets.
Source: 10-K Key Ratios
Financing cash flow was -$1.64B in FY2025, a 37.1% increase in outflows versus the prior year, driven by higher share buybacks and dividends. While shareholder-friendly, accelerating capital returns amid a capital-intensive business model could constrain flexibility if operating conditions deteriorate.
Source: 10-K Cash Flow Statement
Corteva invested $1.47B in R&D in FY2025, representing approximately 8.5% of revenue. While this reflects a strong innovation pipeline, the agricultural biotech and crop protection space is highly competitive, and failure to commercialize R&D investments could impair future growth and returns.
Source: 10-K Income Statement
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue $B | 17.40 $B | 16.91 $B | +2.92% |
Cost of Revenue $B | 9.17 $B | 9.53 $B | -3.75% |
Net Income $B | 1.09 $B | 0.91 $B | +20.62% |
EPS (Basic) $ | 1.60 $ | 1.31 $ | +22.14% |
EPS (Diluted) $ | 1.60 $ | 1.30 $ | +23.08% |
R&D Expense $B | 1.47 $B | 1.40 $B | +5.14% |
SG&A Expense $B | 3.49 $B | 3.20 $B | +9.26% |
Answers draw on this SEC filing and the data on this page
In Q2 FY2026, Corteva reported net sales of $6.38B (down 1.2% YoY) and net income of $1.16B (down 11.6% YoY) while advancing plans to separate its Seed and Crop Protection businesses and executing cost-reduction initiatives.
CTVA delivered strong Q1 FY2026 revenue growth of 11.0% to $4.91B and net income of $720M (+10.4% YoY), though operating cash outflows deepened significantly to -$2.89B, reflecting the seasonal working capital dynamics typical of the agricultural inputs business.
Other companies in Fertilizers & Agricultural Chemicals